Did you find this information helpful?
Certican 0.25mg Tablet
Salt Composition : Everolimus
Manufacturer : NOVARTIS INDIA LTD
Origin of Medicine : Switzerland
10 Tablet(s) In A Strip
Introduction to Certican 0.25mg Tablet
Certrican 0.25mg tablet is an antineoplastic drug belonging to the class of mTOR inhibitors, containing the active ingredient everolimus. It is used to treat advanced breast cancer, renal cell carcinoma, pancreatic neuroendocrine tumours, and also in the treatment of subependymal giant cell astrocytoma (tumours are found in the ventricles of the brain). Good oral hygiene and regular dental check-ups are important during the treatment since this medicine can cause sores or ulcers in the mouth. It is often combined with cyclophosphamide, an alkylating agent, to treat subependymal giant cell astrocytoma. Before taking this medicine, it is necessary to know that your risk of getting bacterial or viral infection increases with this treatment. If you have been infected with Hepatitis B, everolimus increases the chances of reinfection. Tell your healthcare provider if you experience fever, chills, cough, yellowing of the skin, joint pain, or swelling during this treatment. You must limit your exposure to sunlight and UV light by wearing protective clothing and applying sunscreen frequently, as this medicine may increase the risk of developing cancers. Avoid taking grapefruit juice or grapefruit while taking this medicine.
This tablet is not recommended for adolescents and children under the age of 18. Contact your doctor immediately if you experience shortness of breath, chest pain, or worsening cough. During the everolimus treatment, your doctor may periodically monitor your white blood cell counts, platelets, blood sugar, electrolytes, and kidney parameters to prevent serious complications. This medicine has the potential to cause kidney problems. Report to your doctor if you have been diagnosed with liver disorders, heart failure, high blood cholesterol levels, or hypertension before starting this treatment. Avoid live vaccines and close contact with those who have received live vaccines.
Uses of Certican 0.25mg Tablet
- Advanced breast cancer
- Advanced renal cell carcinoma
- Advanced pancreatic neuroendocrine tumours
- Treatment of subependymal giant cell astrocytoma
Therapeutic Effects of Certican 0.25mg Tablet
It contains the active ingredient everolimus, which inhibits the activity of a protein called mammalian target of rapamycin (mTOR), which regulates cell growth. This drug can slow the growth of abnormal cancer cells by blocking the mTOR protein. Everolimus helps to reduce the size of tumours and improve outcomes in patients.
Interaction of Certican 0.25mg Tablet with other drugs
Inform your healthcare provider about all the medicines you take, including prescription medications, over-the-counter medications, nutritional or vitamin supplements, and herbal products. Certain medications may interact with everolimus and reduce effectiveness by causing undesirable side effects.
More Information about Certican 0.25mg Tablet
- Store Certrican 0.25mg tablet in the original package at room temperature (20°C to 25°C).
- Do not freeze.
- Keep it out of reach from children.
How to consume Certican 0.25mg Tablet
Your doctor will decide the dose and duration of everolimus based on the disease condition and other factors. Always take this medicine as prescribed by your doctor. Take the tablet at the same time everyday, with or without food. Do not break, chew, crush, or break the tablet. Swallow the whole tablet with water. If you forgot to take the tablet, simply take your next dose at the scheduled time. Do not take a double dose to make up for a forgotten dose.
Safety Advices for Certican 0.25mg Tablet
Certrican 0.25mg tablet is not recommended for pregnant women as it may cause fetal harm. Consult your doctor if you are pregnant or planning for pregnancy during the treatment.
It is not known if Certrican 0.25mg tablet passes into your breast milk or if it will affect your baby. Please consult your doctor before breastfeeding.
It is not known whether Certrican 0.25mg tablet can be administered to patients with lung problems. Consult your doctor if you have any lung diseases before starting the treatment.
Inform your doctor if you have any liver problems before taking Certrican 0.25mg tablet. Regular monitoring of liver function tests is recommended.
Consuming alcohol may affect the effectiveness of everolimus. Stop consuming alcohol if you are taking this medicine.
It is unsafe to drive vehicles or operate heavy machinery after taking Certrican 0.25mg tablet, it may cause dizziness and impair your concentration.
Side Effects of Certican 0.25mg Tablet
Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them.
- Difficulty breathing, or swallowing
- Swelling of face, lips, tongue, throat
- Severe itching, red rash, raised bumps
- Infection (chills, increased temperature)
- Excessive thirst
- High urine output or severely decreased urine output
- Increased appetite with weight loss
Word of Advice
Certrican 0.25mg tablet have the tendency to cause harm to the unborn foetus. Inform your healthcare provider before starting this treatment if you are pregnant, or have a partner who can become pregnant. Your health care provider will conduct a pregnancy test before you start treatment with everolimus Tablet. Discuss effective birth control methods with your healthcare provider and use them during treatment and for 8 weeks after your last dose. It is not known if everolimus passes into the breast milk. Hence, it is not recommended to breastfeed during this treatment. The occurrence of mouth ulcers or sores is pretty common during this treatment, so your healthcare provider will prescribe a mouthwash. Use the mouthwash as recommended which helps prevent and manage the symptoms.
Q 1. What you should know before taking Certrican 0.25mg tablet?
Before taking Certrican 0.25mg tablet, it is important to know that your risk of getting bacterial or viral infection increases with this treatment. If you have been infected with Hepatitis B, everolimus increases the chances of reinfection. Tell your healthcare provider if you experience fever, chills, cough, yellowing of the skin, joint pain, or swelling during this treatment.
Q 2. Is it safe to use Certrican 0.25mg tablet during pregnancy?
Certrican 0.25mg tablets have the tendency to cause harm to the unborn fetus. Inform your healthcare provider before starting this treatment if you are pregnant, or have a partner who can become pregnant. Your health care provider will conduct a pregnancy test before you start treatment with everolimus Tablet.
Q 3. What are the side effects of Certrican 0.25mg Tablet?
The common side effects that are likely to occur while you are on the treatment with everolimus are fever, chills, skin rash, joint pain, swelling, tiredness, loss of appetite, high risk of infection, mouth ulcers, and difficulty breathing.
Q 4. Is it safe to undergo surgery while on treatment with Certrican 0.25mg Tablet?
Certrican 0.25mg tablet may lead to poor wound healing ability. Therefore, it is advisable to tell your physician if you plan to have any surgery before starting or during treatment with everolimus. Consult your healthcare provider and stop taking everolimus tablets at least one week before planned surgery.
Q 5. Can I drink alcohol while taking Certrican 0.25mg tablet?
It is generally recommended to avoid drinking alcohol while taking Certrican 0.25mg tablet, as alcohol can increase the risk of liver damage.
Fact Box of Certican 0.25mg Tablet
Molecule name: Everolimus
Therapeutic class: Antineoplastics
Pharmacological class: mTOR inhibitors
1.Advanced breast cancer
2.Advanced renal cell carcinoma
3.Advanced pancreatic neuroendocrine tumours
4.Treatment of subependymal giant cell astrocytoma
- Accord Healthcare Limited, Electronic medicines compendium (EMC), [ Revised on Oct 2020] [ Accessed on 18th March 2023], https://www.medicines.org.uk/emc/files/pil.11084.pdf
- Jan Hasskarl; Everolimus; Recent Results in Cancer Research; Published on 2018; Accessed on 18/03/2023; https://pubmed.ncbi.nlm.nih.gov/30069763/
- Novartis Pharmaceuticals Corporation, US Food and Drug Administration, [ Revised on July 2012] [ Accessed on 18th March 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022334s016lbl.pdf
- Goodman & Gilman’s, The Pharmacological Basis of Therapeutics, Targeted therapy: tyrosine kinase inhibitors, monoclonal antibodies and cytokines, 12th edition, 2011, 1743.
- KD Tripathi, Essentials of Medical Pharmacology, Immunosuppressant drugs, 7th edition, 2013, 878 - 882.
MrMed’s primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on MrMed. Our mission is to support, not replace, the doctor-patient relationship.
We maintain strict quality controls on all our partner retailers, so that you always get standard quality products.
100% secure and trusted payment protection
We have a new and dynamic return window policy for medicines and healthcare items. Refer FAQs section for more details.